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Poor sleep is common and increasingly recognized as a poten-tially modifiable risk factor for various physical and mental health problems1,2. Yet, sleep has received little attention from a public health perspective. This may partly be due to the lack of valid descriptions of typical sleep patterns in the general population. Estimating reference ranges for sleep duration can help compare an 
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We aimed to obtain reliable reference charts for sleep duration, estimate the prevalence of sleep complaints across the lifespan 
and identify risk indicators of poor sleep. Studies were identified through systematic literature search in Embase, Medline and 
Web of Science (9 August 2019) and through personal contacts. Eligible studies had to be published between 2000 and 2017 
with data on sleep assessed with questionnaires including ≥100 participants from the general population. We assembled indi-
vidual participant data from 200,358 people (aged 1–100 years, 55% female) from 36 studies from the Netherlands, 471,759 
people (40–69 years, 55.5% female) from the United Kingdom and 409,617 people (≥18 years, 55.8% female) from the United 
States. One in four people slept less than age-specific recommendations, but only 5.8% slept outside of the ‘acceptable’ sleep 
duration. Among teenagers, 51.5% reported total sleep times (TST) of less than the recommended 8–10 h and 18% report 
daytime sleepiness. In adults (≥18 years), poor sleep quality (13.3%) and insomnia symptoms (9.6–19.4%) were more preva-
lent than short sleep duration (6.5% with TST < 6 h). Insomnia symptoms were most frequent in people spending ≥9 h in bed, 
whereas poor sleep quality was more frequent in those spending <6 h in bed. TST was similar across countries, but insomnia 
symptoms were 1.5–2.9 times higher in the United States. Women (≥41 years) reported sleeping shorter times or slightly less 
efficiently than men, whereas with actigraphy they were estimated to sleep longer and more efficiently than man. This study 
provides age- and sex-specific population reference charts for sleep duration and efficiency which can help guide personalized 
advice on sleep length and preventive practices.
A full list of affiliations appears at the end of the paper.
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individual’s sleep characteristics with that of men or women of the 
same age in the general population and quantify the prevalence of 
insufficient sleep at a population level.
The widely used sleep duration recommendations issued by the 
American National Sleep Foundation (NSF)3,4, synthesize relevant 
empirical studies but partly rely on expert opinion, thus may differ 
from data-driven descriptions of sleep in the general population5. 
In addition, these recommendations were targeted for healthy pop-
ulations, whereas the general population may represent a broader 
continuum between health and disease. It is also unclear how the 
three categories of sleep duration (recommended, acceptable and 
not recommended) relate to sleep quality or other sleep complaints. 
Ideally, recommendations for sleep duration in the general popula-
tion should be described over multiple physiologically and clinically 
relevant aspects, including age, sex, demographics or lifestyle. We 
described variations in sleep duration and estimated the proportion 
that falls outside the recommendations and studied factors related 
to suboptimal sleep.
Few epidemiological studies have systematically summarized 
sleep characteristics in the general population. The studies con-
ducted so far have either collected data via mobile devices6 or online 
surveys7,8, have focused on a particular age group such as children9,10 
or older adults11,12, or studied a single sleep problem such as short 
sleep13, long sleep or insomnia14,15. We summarized available infor-
mation in the general population by jointly investigating multiple 
sleep variables across the lifespan. Importantly, as opposed to pre-
vious meta-analytical efforts16–18, also of similar sample sizes19, we 
assembled individual participant data (IPD) from 200,358 people 
aged 1 to 100 years, from 36 population-based studies from the 
Netherlands. This allowed us to explore sleep characteristics in 
various subgroups as well as interrelations between sleep indices. In 
addition, we compared the available estimates with those from two 
Table 1 | Time in bed, total sleep time and sleep efficiency, stratified by age and sex
Strata by age 
and sex
Time in bed (h) Total sleep time (h) Sleep efficiency (%)
Studies (20, 1998–2013)a Studies (15, 1993–2015) Studies (15, 2002–2013)
n Mean ± s.d. n Mean ± s.d. n Mean ± s.d.
1–2 years
 Total 3,240 11.7 ± 0.72 – – – –
 Male 1,594 11.6 ± 0.73 – – – –
 Female 1,646 11.7 ± 0.70 – – – –
3–5 years
 Total 6,421 11.5 ± 0.6 1,266 11.6 ± 0.6 1,183 99 ± 2
 Male 3,241 11.4 ± 0.6 653 11.5 ± 0.6 604 99 ± 2
 Female 3,180 11.5 ± 0.6 613 11.6 ± 0.6 579 99 ± 3
6–13 years
 Total 18,905 10.8 ± 0.9 8,377 10.6 ± 1.0 6,931 97 ± 5
 Male 9,477 10.7 ± 0.8 4,185 10.5 ± 0.9 3,461 97 ± 5
 Female 9,420 10.8 ± 0.9 4,189 10.6 ± 1.1 3,468 97 ± 5
14–17 years
 Total 3,747 8.8 ± 0.8 513 7.7 ± 1.1 509 91 ± 8
 Male 1,745 8.7 ± 0.8 189 7.9 ± 1.0 186 92 ± 7
 Female 2,000 8.8 ± 0.8 324 7.6 ± 1.1 323 91 ± 8
18–25 years
 Total 1,174 8.3 ± 1.2 5,192 7.5 ± 1.1 - -
 Male 588 8.0 ± 1.2 2,049 7.4 ± 1.1 - -
 Female 606 8.5 ± 1.1 3,143 7.6 ± 1.0 - -
26–40 years
 Total 23,896 8.0 ± 0.9 38,635 7.2 ± 0.9 21,204 89 ± 9
 Male 9,938 7.7 ± 0.9 16,182 7.1 ± 0.9 8,678 90 ± 8
 Female 13,931 8.1 ± 0.8 22,453 7.3 ± 1.0 12,526 89 ± 10
41–65 years
 Total 51,086 7.8 ± 0.9 93,837 7.0 ± 1.1 49,513 90 ± 10
 Male 21,235 7.5 ± 0.9 40,603 6.9 ± 1.0 20,570 92 ± 9
 Female 29,851 7.9 ± 0.9 53,234 7.1 ± 1.1 28,943 89 ± 10
>65 years
 Total 5,480 7.9 ± 1.1 8,195 7.0 ± 1.3 4,922 88 ± 13
 Male 2,288 7.9 ± 1.1 3,504 7.2 ± 1.2 2,021 90 ± 11
 Female 3,192 7.8 ± 1.1 4,691 6.8 ± 1.4 2,901 86 ± 14
aStudies are shown as number of studies and related time period. Prevalence was not calculated if <200 participants in a cell.
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large population-based adult samples from the United Kingdom 
(n = 471,759) and the United States (n = 409,617).
This study provides reliable estimates of self-reported sleep dura-
tion, sleep timing and sleep efficiency but also perceived sleep qual-
ity, insomnia symptoms and other sleep complaints (non-restorative 
sleep, sleepiness, snoring and use of sleep medication) in the gen-
eral population. To obtain valuable population percentile curves 
and reference values we described sleep duration, time in bed and 
sleep efficiency across age and sex. We also explored educational 
level, ethnic origin, partnership and employment status, as well as 
body mass index (BMI) and smoking, as potential risk indicators 
associated with these sleep variables. Where data were available, we 
complemented subjective data with objectively estimated sleep vari-
ables. Moreover, we evaluated consistency and differences in sleep 
parameters across populations from the Netherlands, the United 
Kingdom and the United States.
Results
We included 34 studies, identified by systematic review, including 
200,358 participants from the Netherlands between the ages of 1 
and 100 years. Additionally, 471,759 people (40–69 years, 55.5% 
female) from the United Kingdom and 409,617 people (≥18 years, 
55.8% female) from the United States were included. Population 
characteristics of the studies identified in the systematic review are 
presented in Supplementary Table 1. Compared to data of the 2011 
Dutch Census20, females in age groups between 10 and 80 years were 
slightly over-represented (ranging from a 1 to 9% difference). People 
in both the high (χ2 = 60.1 (1), P < 0.001, 0.9% difference, 95% con-
fidence interval (CI) = 0.7; 1.1, 29.9% versus 29.0%) and the middle 
(χ2 = 596.2 (1), P < 0.001, 2.9% difference, 95% CI = 2.7; 3.1, 37.3% 
versus 34.4%) educational level were slightly over-represented in 
our sample, compared to the population in the Dutch Census of 
2011. Study-specific sleep estimates are provided in Supplementary 
Table 2.
Time in bed, sleep duration and sleep efficiency. Adults 
(≥18 years) reported a mean ± s.d. time in bed (TIB) of 7.8 ± 0.9 h, 
a total sleep time (TST) of 7.1 ± 1.0 h and a sleep efficiency (SE) of 
89 ± 9% (Table 1). Short sleep duration (TST < 6 h) was reported 
by 6.5% of this population, whereas 25.8% reported a TST of <7 h. 
Population percentile curves of TST and SE across age catego-
ries defined by NSF recommendations are shown in Fig. 1 and in 
Supplementary Fig. 2 for age (continuous). Although 24.5% of the 
population sleeps less than the recommended sleep duration for 
age, only 5.6% fall outside of the ‘acceptable’ ranges (Supplementary 
Table 3). More than half (51.5%) of those aged 14–17 years reported 
sleeping less than recommended 8–10 h per night. Teenagers in the 
25th percentile sleep 54 min less, whereas those in the 10th percen-
tile sleep 96 min less than recommended. In all other age groups, 
even the 5% and 95% percentile groups, sleep duration was in the 
‘acceptable range’ as defined by the NSF (ref. 3). SE decreases from 
mean ± s.d. = 97 ± 5% in childhood to 91 ± 8% in teenage years. This 
SE decline continues into adulthood; however, 25% of those aged 
>65 years reported sleeping over 95% of their TIB.
Sex difference were observed from adulthood onwards (Table 1). 
Adult women reported a longer TST (t = 25.9 (145,840), B = 0.14 h, 
P < 0.001, 95% CI = 0.13; 0.21) but a marginally lower SE (t = -34.1 
(75,739), P < 0.001, B = –0.02%, 95% CI = −0.03; −0.02) than men 
(Supplementary Table 4). For example, women between 41 and 
65 years of age sleep on average 7.1 ± 1.1 h, whereas at the same age 
men sleep on average 6.9 ± 1.0 h per night. However, the women 
sleep 89 ± 10% of the TIB, whereas men sleep 92 ± 9% of the TIB. 
From about 14 years onwards, the between-person variation in TIB 
increases substantially, more so for men than for women (Fig. 2). 
Sex-specific TIB percentiles using age (continuous) are shown in 
Supplementary Fig. 3. From 14 years onwards bedtime is gradually 
delayed, whereas wake time remains stable at around 7:00 across 
the lifespan (Fig. 3). Poor sleep quality is most prevalent in people 
(≥18 years) spending <6 h in bed, whereas difficulty initiating sleep 
is most commonly reported by those spending ≥9 h in bed (Fig. 4).
We found that TIB is longer on weekend days than on week days 
only for age groups that go to school or work. In young children 
and older adults, the TIB on week days and weekend days is roughly 
equal. The week day – weekend difference increases as children start 
going to school (median difference of 30 min), peaks in teenagers 
(median difference of 75 min) and is around 60 min in working 
adults.
Heterogeneity estimates were high: I2 ranged between 97 and 99% 
for TIB, 90 and 99% for TST and 96 and 99% for SE (Supplementary 
Table 5). However, when meta-analyses were stratified by sex, 
heterogeneity estimates decreased to values as low as 0% for TIB 
(women, 26–40 years), 54% for TST (women, 18–25 years) and 0% 
for SE (both men and women, >65 years). For some age strata, how-
ever, sex and age stratification had minor effects on heterogene-
ity estimates, as I2 remained high (up to 100%) (see forest plots in 
Supplementary Fig. 4a–c). Importantly, age- and sex-specific TIB, 
TST and SE estimates changed only marginally from the fixed-effect 















































































































Fig. 1 | Age-specific percentile curves of TST (n = 164,069) and SE (n = 76,746). a, Percentiles of sleep duration per age group, where the grey area 
represents the nSF recommended sleep duration. b, Percentiles of SE (percentage of sleep within TIB: (TST/TIB) × 100) per age group.
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Daytime napping. As expected, most children nap in the first 
3 years (80% of 1–2-year-olds, 65% of 3-year-olds). Napping is less 
common during school age (12.7% of 6–13-year-olds nap) and 
adulthood (13.7% of people between 26 and 64 years nap regularly), 
than in people aged >65 years (27%).
Insomnia symptoms. Symptoms of insomnia (difficulty initiating 
sleep (DIS), difficulty maintaining sleep (DMS) and early morn-
ing awakening (EMA)) increase from childhood (3–5 years: 4% 
DIS, 6% DMS) into adolescence (6–13 years: 13% DIS, 9% DMS). 
In adulthood, insomnia symptoms are least frequent in those 
aged 26–40 years and most frequent in those >65 years (Table 2). 
DIS is most prevalent in those aged 18–25 years (22.6%), whereas 
DMS (23.2%) and EMA (23.5%) are most prevalent in those 
>65 years. Sex difference in insomnia symptoms become evident 
only in puberty (that is, for 14–17-year-olds, males versus females: 
12% versus 19% DIS, 16% versus 28% DMS). In adults, women are 
at increased odds for DIS (z = 34.8 (108,447), P < 0.001, OR = 2.26, 
95% CI = 2.16; 2.36), DMS (OR = 2.05, 95% CI 1.91; 2.19) or 
EMA (z = 19.7 (28,041), P < 0.001, OR = 1.49, 95% CI = 1.37; 1.62; 
Supplementary Table 6) compared to men, after adjusting for demo-
graphic factors.
Heterogeneity ranged from 0 to 99% for DIS, 0 to 97% for DMS 
and 17 to 97% for EMA, depending on age group (Supplementary 
Table 7). Heterogeneity of insomnia symptoms was low in paediatric 
cohorts aged 5 years or younger. When studies of adults were addi-
tionally stratified by sex, I2 decreased to values as low as 48% for DIS 
in men aged >65 years, 54% for DMS in women aged 26–40 years 
and 0% for EMA in men aged 18–25 years. However, residual het-
erogeneity was substantial in most other strata (Supplementary 
Table 7 and Supplementary Fig. 5a–c). Pooled prevalence estimates 
(Supplementary Table 7) were comparable between fixed-effect 
and random-effect models, with the exception of DIS in the age 
groups 18–25 and 26–40 years (23.4–9.5%), DMA in ages 6–13 years 
(9–17%) and EMA in ages 26–40 years (14–11%) and 41–65 years 
(21–17%).
Other sleep complaints. Sleepiness is most prevalent in teenagers 
(20.4%; Supplementary Table 8). Although there are no clear sex 
difference in sleepiness, non-restorative sleep is more prevalent 
in women than in men. Women also use sleep medication more 
often (8.6% versus 5.2% in age group 26–40 years, to 17.5% versus 
6.3% in >65 years). Snoring is more commonly reported in adult 
men than in women (40.2% versus 23.2%), although this difference 
becomes less pronounced at older ages (Supplementary Table 8).
Associations of sociodemographics with sleep characteristics in 
adults. Adults with a low educational level did not differ in TST 
(t = –1.3 (145,840), P = 0.191, B = −0.01 h, 95% CI = –0.02; 0.00) 
compared to highly educated adults but reported a marginally lower 
SE (t = −5.2 (75,739), P < 0.001, B = –0.01%, 95% CI = −0.03; −0.00). 
In addition, people living in the Netherlands with a non-European 
ethnic origin sleep shorter (t = −21.4 (145,840), P < 0.001, 
B = –0.30 h, 95% CI: −0.34; −0.30) and less efficiently (t = −7.02 
(75,739), P < 0.001, B = −0.03%, 95% CI = –0.03; –0.02, P < 0.001) 
compared to people with Dutch ethnic origin. Similarly, both low 
education and non-European ethnic origin were risk indicators for 
insomnia symptoms in the Netherlands (Supplementary Table 6). 
Having paid employment and a partner were both associated with 
longer sleep duration and less insomnia symptoms, independent 
of demographics (Supplementary Tables 4 and 6). Unadjusted esti-
mates stratified by ethnic origin, educational level, employment 
and presence of a partner are presented in Supplementary Table 9. 
Results were similar if participants >90 years (n = 130) were 































































































































Fig. 3 | Sleep timing across lifespan. night-time sleep timing across the 
lifespan (n=106,282).
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Association of health risk indicators with sleep characteristics 
in adults. In adults, we observed 2.4 min (95% CI: −3.6; −1.8) 
shorter TST for overweight (BMI >25 kg/m2; t = −6.8 (145,832), 
P < 0.001, B = −0.04, 95% CI = −0.06; −0.03) and 6.6 min (95% CI: 
−7.2; −5.4) shorter sleep in people who are obese (BMI >30 kg/m2; 
t = −12.7 (145,832), P < 0.001, B = −0.11, 95% CI = −0.12; −0.09), 
compared to people with normal weight. People who are obese, but 
not those who are overweight, had a marginally lower SE (t = –12.6 
(145,832), P < 0.001, B = −0.004%, 95% CI = −0.01; −0.00) and 
also experienced more DIS (z = 5.3 (108,444), P < 0.001, OR = 1.08, 
95% CI = 1.02; 1.17; Supplementary Table 4). Both former and cur-
rent smokers reported sleeping shorter relative to non-smokers 
and current smokers also reported a lower SE. Current smokers 
experienced more DIS but experienced less DMS (Supplementary 
Table 6). Estimates stratified by BMI and smoking status are pre-
sented in Supplementary Table 10.
Complementing subjective with objective sleep data. TIB and 
TST were between 0.4 and 1.9 h shorter when estimated with 
actigraphy as compared to sleep diary reports of the same nights 
(Supplementary Table 11). Similarly, actigraphic SE estimates were 
lower compared to diary estimates, averaging 9.7 ± 7% difference 
(tpaired = –51.6 (1,307), P < 0.001, M = –0.097, 95% CI = –0.10; –0.09) 
in the Generation R sample, and 9.6 ± 9% difference (tpaired = –38.1 
(1,926), P < 0.001, M = –0.095, 95% CI = –0.09; 0.10) in the 
Rotterdam Study sample. The sleep diary SE estimates were also 
lower than those computed from the pooled IPD, except for the 
group of teenagers where SE based on pooled IPD was estimated 
to be 91 ± 8%, compared to 95.6 ± 4% estimated by sleep diary. 
According to actigraphic TST estimates, more than 80% of the pop-
ulation, sleeps less than the US recommendations (Supplementary 
Table 12). The proportion of people sleeping less than the ‘accept-
able’ TST ranged between 16.3 and 38.7% in the paediatric cohort 
and between 9.4 and 47.3% in the older adults, as measured with 
actigraphy. Actigraphic sleep parameters of the adults from the 
Netherlands were compared with respective values from adults 
in the United Kingdom (Supplementary Table 13). Both TIB and 
TST were ≥1 h longer in the UK cohort regardless of age and sex, 
however SE differences were small between 1.6% (t = 7.9 (48,994), 
P < 0.001, M = 1.6, 95% CI = 1.2; 2.0) and 2.1% (t = 7.7 (38,439), 
P < 0.001, M = 2.1, 95% CI = 1.6; 2.6). Women (>41 years) reported 
sleeping slightly shorter times and/or less efficiently than men both 
in sleep diaries and sleep questionnaires, whereas actigraphy esti-
mates indicate the opposite: women sleep longer and slightly more 
efficiently than men of similar age (Supplementary Table 11). This 
was also found in the UK Biobank (UKBB) cohort.
International comparisons. Average self-reported TST as well as 
sex difference in TST were similar in the adult Dutch, UK and US 
populations (Supplementary Table 14). The proportion of adults 
reporting TST shorter than recommended for age was the highest in 
the the United States (30.3%), compared to 24.5% in the Netherlands 
and 25.0% in the United Kingdom. The proportion of adults sleep-
ing less than the ‘acceptable’ values was below 10% in all three 
countries. The prevalence of insomnia symptoms (Supplementary 
Table 15) was 1.5–2.9 times higher in the US sample (for DIS and 
DMS, across adult ages with the exception of those aged 18–25 years) 
than in the Netherlands. Sex and age differences in insomnia symp-
toms were similar across populations: DIS reduced and DMS 
increased with advanced age, whereas women reported insomnia 
symptoms more commonly irrespective of age.
Changes in sleep patterns with calendar year. In the data from the 
Netherlands there was some evidence for a decrease in sleep dura-
tion from the 1990s to the 2000s; TST values between 1993 and 1997 
averaged around 7.3 h per night. After 2004, values ranged between 
6.7 and 7.1 h, with the exception of 2009 which is fully based on 
the LASA Study (Supplementary Fig. 6). In the United States, TST 
values between 2004 and 2017 were more stable, ranging between 
7.07 h in 2017 and 7.19 h in 2007. There were no changes in the 
prevalence of insomnia symptoms across the years of the studies in 
the Netherlands and in United States (Supplementary Fig. 7).
Discussion
Our results suggest that: (1) the population of the Netherlands 
reported sleeping within ‘acceptable’ sleep duration range at all 
ages but more than half of teenagers slept almost an hour less 
than recommendations; (2) actigraphic sleep duration and effi-
ciency are consistently lower than self-reported estimates, which 
limits the applicability of current recommendations to objective 
sleep variables; (3) insomnia symptoms were least frequent in 
26–40-year-olds and most frequent in people aged >65 years, and 
those spending >9 h in bed; (4) self-reported TST did not differ 
substantially between adults from the Netherlands and from the 
United Kingdom and the United States but insomnia symptoms 
were 1.5–2.9 times more prevalent in the United States than in the 
Netherlands; (5) poor sleep quality and insomnia symptoms were 
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Fig. 4 | Prevalence of having difficulty initiating sleep (n = 95,603) and ‘poor’ sleep quality (n = 77,854), across different durations of time in bed. Data 
on DMS, EMA and TIB were not available.
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non-European origin, people who are overweight and smokers were 
particularly prone to experiencing poor sleep.
In this large descriptive sleep study, pooling many individual 
studies inevitably results in high heterogeneity, thus absolute esti-
mates should be interpreted with caution. Several methodologi-
cal issues must be discussed. First, variables such as sleep timing 
and duration may be more objectively assessed with actigraphy or 
polysomnography21,22. However, subjective complaints are clini-
cally relevant and highly related to daily functioning. Moreover, 
the implementation of measures such as polysomnography in 
large-scale population-based studies is currently limited. In this 
study we were able to complement subjective data with objective 
sleep parameters in teenagers and older adults. These are the two 
age groups with the highest prevalence of insufficient sleep dura-
tion. Sleep duration estimates differ by method of assessment but 
habitual sleep duration is reasonably stable within individuals23,24. 
Thus, the interindividual differences in sleep duration can reliably 
be compared when assessed with the same method only. Moreover, 
absolute numbers should be interpreted with caution because age 
or reporter could influence sleep estimates (for example, parents 
may under-report their children’s sleep onset latency and wake time 
during the night, resulting in higher SE estimates). In addition, as 
SE is based on two self-reported measures, these variables might 
be particularly prone to error and should be interpreted with cau-
tion. Second, heterogeneity between studies may have introduced 
misclassification bias (for example, different definitions of bedtimes 
and wake times can influence TIB estimates). Analyses of sources 
of heterogeneity indicated that age and sex only partly account 
for the heterogeneity between the studies from the Netherlands 
and that most remaining heterogeneity probably originates from 
between-study differences in sampling, source population, regions 
or missing patterns. Other sociodemographic variables, within and 
beyond those assessed in this study, probably also influence sleep 
estimates and may account for residual heterogeneity. Although 
access to IPD improves data quality through standardization of def-
initions, this study was not sufficiently powered to tease out these 
influences on heterogeneity. Nevertheless, we provided crude esti-
mates for sociodemographic strata, that could be valuable reference 
for future studies or clinical practice. Third, we could not assess 
potential confounding by underlying sleep disorders (for example, 
sleep apnoea), psychiatric disorders, substance abuse and other 
chronic medical conditions that could disturb sleep and the ability 
to go out of bed (for example, hypertension and diabetes mellitus), 
environmental (screen exposure and noise) or occupational factors 
(noise and shift work). In addition, differential recruitment strate-
gies may have resulted in differential prevalence of disturbed sleep 
in the sample. These factors may have contributed to heterogeneity 
in the sleep estimates. Fourth, although we studied a representa-
tive large population sample of the Netherlands and compared sleep 
estimates to other populations from developed countries, findings 
may not be generalizable to populations with different sociodemo-
graphic or cultural characteristics. These international comparisons 
were possible for some sleep parameters only. However, all studies 
sampled participants from the general population, which reduces 
the chance of selection bias and increases the interpretability of the 
comparisons. Fifth, multivariable adjusted models indicated that 
the reported differences in sleep patterns across sociodemographic 
groups were small, thus their clinical implications may be limited.
In our study, 25% of the adult population reported sleeping less 
than the recommended 7–9 h, whereas the Centers for Disease 
Control and Prevention has estimated up to 44.1% of the US popu-
lation aged ≥18 years slept less than 7–9 h (ref. 25). We showed that 
the average self-reported sleep duration does not differ between the 
Netherlands, the United States and United Kingdom but the preva-
lence of sleeping below the recommended TST was higher in the US 
population (30%), than in the European populations (24–25%). In 
the Netherlands, there was some evidence for a 18–36 min decrease 
in the average sleep duration from the 1990s to the 2000s but this 
could also have resulted from between-study heterogeneity. We did 
not observe changes in average sleep duration in the United States, 
although one study26 reported an increase in the prevalence of 
adults sleeping <6 h per night on the basis of the same data. We also 
showed that the recommendations are only applicable to subjective 
sleep reports. Specifically, 80% of participants >40 years, have an 
actigraphic TST less than the ‘recommended’ 7 h TST. It is important 


















n % n % n %
1–2 years
 Total 1,336 4.5 – – – –
 Male 655 4.9 – – – –
 Female 681 4.1 – – – –
3–5 years
 Total 5,484 4.0 1,678 6.1 nD nD
 Male 2,778 4.2 834 6.6 nD nD
 Female 2,704 3.8 844 5.7 nD nD
6–13 years
 Total 13,227 13.2 7,210 9.1 nD nD
 Male 6,697 12.3 3,601 7.9 nD nD
 Female 6,570 14.0 3,602 10.2 nD nD
14–17 years
 Total 1,631 16.5 1,175 23.2 – –
 Male 719 12.9 501 16.8 – –
 Female 910 19.3 672 28.1 – –
18–25 years
 Total 2,227 22.6 1,961 9.4 2,023 10.3
 Male 969 19.4 856 8.6 892 9.2
 Female 1,252 25.1 1,105 10.0 1,131 11.2
26–40 years
 Total 26,264 7.2 3,795 11.3 1,636 14.1
 Male 10,850 5.5 1,550 7.4 722 12.0
 Female 15,413 8.3 2,244 13.9 913 15.7
41–65 years
 Total 73,648 9.3 19,056 15.7 8,417 21.0
 Male 31,637 5.4 8,640 10.5 3,904 17.5
 Female 41,975 12.3 10,416 20.1 4,513 24.0
>65 years
 Total 8,869 14.9 3,255 20.2 3,376 23.5
 Male 3,841 8.0 1,527 14.5 1,579 18.3
 Female 5,028 20.2 1,728 25.3 1,797 28.0
aStudies are shown as number of studies and related time period. Prevalence rates were not 
calculated if <200 participants in a cell. nD, not defined if inapplicable for the age group.
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to note that a portion of this population still falls within the ‘accept-
able’ range of 6–11 h developed by the NSF expert panel3,4. The 
pooled IPD data show that 6.8% of the adult population report 
sleeping less than the ‘acceptable’ 6 h but this increased to 25% at an 
older age. Using actigraphic TST estimates up to 47% adults were 
estimated to sleep less than the ‘acceptable’ values. On the basis of 
an online questionnaire, Kerkhof has reported a higher percentage 
(30.4%) of <6 h of sleep in an adult population from the Netherlands7. 
Studies included in our meta-analysis have shown that participants 
aged 18–65 years sleeping both <6 h (ref. 27) and <7 h (ref. 28) per 
night have higher cardiovascular risk as compared to those sleeping 
7–8 h per night, as confirmed by landmark meta-analyses on the 
associations between sleep and cardiometabolic health29,30. A Time 
Use Survey Panel in industrialized countries in Europe and North 
America31 has also shown that older adults sleeping <7 h have lower 
self-reported health, although the ‘acceptable’ sleep duration for this 
age group can be as short as 5 h per night. It thus remains unclear 
what the appropriate amount of self-reported sleep duration is for 
preserving health and reference values for objective sleep dura-
tion are unknown. In teenagers, the prevalence of insufficient sleep 
and sleepiness was much higher than in any other age group. This 
could probably be explained by developmental bedtime delay (as 
evidenced by our analyses of sleep timing) but could also be influ-
enced by adolescent lifestyle and environment such as social and 
peer pressure, screen exposure or social life.
Despite the premise that ‘optimal’ sleep duration probably differs 
per outcome, individual and circumstances, providing reference val-
ues for sleep length can be useful in clinical or prevention practice. 
This way it is possible to estimate the extent of the problem (that 
is, the proportion that falls outside of recommended values) which 
could guide public health policies for improving sleep in the gen-
eral population. Therefore, we estimated sleep duration percentile 
curves, which so far have been estimated only in children and ado-
lescents9,10,32. Healthcare professionals can easily assess sleep char-
acteristics by interviews or questionnaires but with increased use of 
accelerometers in research and daily settings, reference curves for 
actigraphic sleep variables should also be estimated.
Several previous observational studies have estimated the 
prevalence of insomnia in European populations7,11,14,15,33. Our 
study estimates (7–23% depending on insomnia symptom and age 
group) largely correspond with those reported in telephone inter-
views by 25,579 people from seven European countries in the 
1990s14. The prevalence of DIS and DMS in the Netherlands, 
however, was substantially lower than in the United States. Our 
study, adds age-specific information on the prevalence of insom-
nia symptoms across the lifespan and shows which insomnia 
symptoms are most common in each age group. We also show that 
these age-related changes in insomnia symptoms are similar in the 
United States. This information could be used to improve sleep on 
a population level; that is, young adults would probably benefit 
from interventions tackling difficulty initiating sleep, whereas older 
adults might need help with sleep maintenance or early morning 
awakenings. We also show that spending 7–8 h in bed is associated 
with better sleep quality and fewest insomnia symptoms, simi-
lar to a general-population study in Norwich, United Kingdom11. 
Importantly, our data also show that wake time is remarkably stable 
across the lifespan, thus any interventions targeting sleep duration 
but also those targeting sleep quality should primarily be aimed at 
adaptations of bedtime.
In line with previous reports based on smaller samples, we found 
using pooled IPD data that women report longer sleep duration but 
slightly lower sleep efficiency7,11. For example, a 28-year-old woman 
reporting to spend 9 h in bed is in the 90th percentile of the female 
population of similar age, whereas, a 28-year-old man with the 
same TIB, would be in the 95th percentile of the male population 
of similar age. When measured with actigraphy, however, women’s 
sleep was slightly longer and more efficient than that of men in the 
Netherlands and in the United Kingdom. Women experience more 
insomnia problems than men in all three countries. This indicates 
that recommendations for appropriate sleep duration and quality 
should be sex-specific. This commonly reported difference7,14,33,34 
emerges during puberty, suggesting sex hormones, among other 
social factors such as stress or parenting, might play a role in the 
development of insomnia problems. Interestingly, women do not 
report daytime sleepiness more often, despite experiencing more 
insomnia problems and using more sleep medication than men.
The estimated population reference charts for sleep timing, 
sleep duration and efficiency across the lifespan, will help guide per-
sonalized advice on sleep. However, current recommendations are 
applicable only to self-reported average sleep duration and inter-
national differences point to the need for country-specific recom-
mendations for adequate sleep. Given that poor sleep (low sleep 
quality or insomnia symptoms) is more common than short sleep 
(TST below ‘acceptable’ values) in Europe and in the United States, 
recommendations for improving sleep might need to focus more 
on sleep quality. Whereas most available guidelines address optimal 
sleep duration, our findings highlight the importance of also target-
ing sleep quality. Importantly, we identified subgroups that are prone 
to shorter or less efficient sleep, such as teenagers, women, people of 
non-European origin, those with obesity and smokers. These popu-
lation strata could be used as sampling schemes when developing 
interventions to improve sleep at a population level. We also show 
that the lowest prevalence of poor sleep in the general population 
occurs in those spending 7–8 h in bed. This finding, together with 
the relatively high prevalence of poor sleep despite nearly appropri-
ate sleep duration, warrants defining new targets for sleep hygiene 
advice. In other words, by recommending optimal sleep duration we 
are unlikely to accomplish better sleep at a population level.
Methods
Search strategy, eligibility and selection criteria. To chart sleep characteristics 
for the population of the Netherlands, we conducted a systematic literature 
search to identify population-based cohorts assessing sleep characteristics via 
questionnaires. We searched Embase, Medline Ovid and Web of Science Core 
Collection on 9 August 2019 with a search strategy developed by a biomedical 
information specialist (W.B.; Supplementary Text). Inclusion criteria were:  
(1) population-based sample from the Netherlands; (2) inclusion of at least 100 
participants older than 1 year; (3) assessment of sleep with questionnaires;  
(4) publication in a peer-reviewed journal after the year 2000. Exclusion criteria 
and steps are outlined in a detailed flowchart (Supplementary Fig. 1a,b). All 5,750 
identified abstracts were checked for eligibility by two independent reviewers  
(D.K. and either T.S.L., Y.X., M.E.K.V. or I.D.; references were split randomly), after 
which D.K. assessed 381 full-text articles for eligibility and T.S.L. again assessed 
the excluded articles. From 142 publications that met our inclusion criteria, we 
identified 43 non-overlapping study populations. We additionally added four 
studies identified by personal contacts but sought IPD from 44 studies (IPD was 
not requested from three studies that were published after data collection had 
been completed in early 2017), of which 36 agreed (response 81%). From studies 
with repeated measurements, the baseline measurement was used for this IPD as it 
comprised the largest sample size.
All studies included in the meta-analysis (Supplementary Table 1) were 
approved by the ethics committee of the local university, institute or organization. 
Written informed consent was obtained in the original studies from all participants 
or caregivers (see publications in Supplementary Table 1). The first and 
corresponding authors obtained legal rights for access to anonymized datasets. 
This article follows the preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) statement for IPD reporting guidelines, Supplementary 
Text (ref. 35).
To evaluate differences of sleep characteristics across countries, we included 
two large population-based datasets from adults in the UKBB (n = 498,320) and 
the National Health Interview Survey (NHIS) from the United States (n = 409,617). 
These samples were not meta-analytically pooled with the data from the 
Netherlands, as this would further increase heterogeneity, thereby resulting in 
estimates that cannot be better generalized to other populations.
Public involvement. This research is a response to public interest. In April 2015, 
residents of the Netherlands were asked to indicate which scientific questions 
should be addressed in the next decade. Requests of 11,700 people laid the 
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foundation for the National Science Agenda (https://wetenschapsagenda.nl/). Text 
analysis revealed that attention to sleep-related issues was requested 423 times; 
hence the current research question can be considered relevant by the general 
population. However, participants were not invited to comment on the study 
design or interpretation of the results. Participants did not contribute to the writing 
or editing of this document for readability or accuracy.
IPD coding. To maximize internal validity, we harmonized the datasets in a 
three-step procedure: (1) we agreed upon definitions for each sleep variable 
(described in the ‘Coding steps and protocol’ of the Supplementary Text), also 
sociodemographic variables were classified in line with Statistics Netherlands36,37; 
(2) two independent coders (D.K. and T.S.L.) coded all datasets according to the 
standardized protocol (reliability statistics reported in ‘Coding steps and protocol’, 
Supplementary Text); and (3) coding disagreements were resolved by consensus 
supervized by a senior sleep researcher (H.T.).
Sleep variables. We distinguished the following ten sleep variables:
 1. Time in bed (TIB, h) was calculated as the difference between bedtime 
and wake time in hours, for week days and weekends separately. Bedtimes 
between 12:00 and 17:00 and wake up times between 17:00 and 02:00 were 
excluded (n = 97).
 2. Sleep duration (total sleep time, TST, h) was self- or caregiver-reported, 
values ≤2 h or ≥20 h were excluded (n = 81).
 3. Sleep efficiency (SE, %) was calculated as (TST/TIB) × 100. Note that TST and 
bedtimes/wake times were assessed separately, which may result in implausi-
ble values, for example TST of 7.5 and TIB between 23:00 and 07:00 results in 
implausible SE but probably represents high SE. To balance bias in estimates 
with loss of precision: values between 100 and 110% were recoded to 100% 
(mainly errors in reporting times, n = 7,630, 8.8%), values above 110% were 
excluded (n = 2,597, 2.9%, most from the largest cohort, Lifelines Study).
 4. Daytime napping was defined as reporting ‘regularly’ or ‘frequently’ sleeping 
≥30 min during the day (yes/no).
 5. Insomnia symptoms (yes/no) included difficulty initiating sleep (DIS), de-
fined as trouble falling asleep (≥30 min); difficulty maintaining sleep (DMS), 
defined as trouble falling asleep again after nocturnal awakening; and early 
morning awakening (EMA), defined as waking up earlier than desired and 
not being able to fall asleep anymore. Insomnia symptoms were present if 
symptoms were reported to occur often, frequently or ≥3 times per week38.
 6. Sleep medication was defined as the reported use of any medication to aid 
sleep at least once a week (yes/no).
 7. Non-restorative sleep was defined as not feeling rested when waking up in the 
morning, reported at least ‘often’ or ≥3 times per week (yes/no).
 8. Sleepiness was defined as ‘feeling sleepy’ during the day, reported at least 
‘often’ or ≥3 times per week (yes/no).
 9. Snoring was present if snoring was reported at least once a week (yes/no).
 10. Poor sleep quality was present if any questions on how individuals perceived 
or judged their habitual sleep were answered with ‘bad’, ‘unsatisfactory’, 
‘insufficient’ or similar qualifications (yes/no).
Sociodemographic variables. Ethnic origin for the samples from the Netherlands 
was based on self-report of the country of birth of the participant or his/her 
parent39 and categorized into European origin—Dutch and European origin— 
other and non-European origin37. Educational level was based on self-reported 
highest education and categorized into low (lower vocational training or  
≤3 years at general secondary), medium (>3 years general secondary school, 
intermediate vocational training or first year of higher vocational training) or high 
(university degree, higher vocational training)36. Having paid employment and 
having a partner (including non-cohabiting) were self-reported and classified as 
yes/no.
Health risk indicators and lifestyle variables. Smoking was self-reported and 
categorized into: never, former or current smoker. BMI (kg m–2) was calculated on 
the basis of self-reported or measured weight and height. BMI of 18.5–25 kg m–2 
was defined as normal weight. Underweight was defined as BMI <18.5 kg m–2, 
overweight as BMI >25 kg m–2 and obese >30 kg m–2. These variables were only 
defined for adults.
Complementary objective sleep estimates. In two cohorts from the Netherlands, 
subjective sleep reports were collected simultaneously with sleep diaries and 
actigraphy. In the Generation R Study, children aged 10–15 years (n = 1386) wore 
Geneactiv watches for 9 d (ref. 40). In the Rotterdam Study, participants aged 
45–98 years (n = 1,940) wore Actigraphy watches for 7 d (ref. 41). Actigraphic 
sleep variables were estimated with validated algorithms. Actigraphy and diary 
sleep estimates were averaged across days. The actigraphic sleep variables were 
complemented by those of 85,499 participants from the UKBB (ref. 42).
International comparisons. To evaluate consistency across countries, the IPD 
analyses were complemented by data from international cohorts. First, the UKBB 
(https://www.ukbiobank.ac.uk) is a large population-based cohort study aimed at 
improving prevention, diagnosis and treatments of various illnesses. Between 2006 
and 2010, ~9.2 million people aged 40–69 years were invited to participate. Second, 
US data were obtained from the NHIS (https://www.cdc.gov/sleep), harmonized by 
Integrated Public Use Microdata Series (https://nhis.ipums.org/nhis/), a nationally 
representative survey of non-institutionalized American adults surveyed annually 
(2004–2017). We included adults aged 18–84 years with non-missing responses for 
the respective sleep measures.
In the UKBB, adults reported on TST by answering the question ‘About how 
many hours sleep do you get in every 24 hours? (please include naps)’. We excluded 
participants reporting usual daytime napping from the UKBB (n = 26,561). NHIS 
participants answered the question ‘On average, how many hours of sleep do 
you get in a 24-hour period?’, with responses in hour increments. Symptoms of 
insomnia in the UKBB were assessed by the question: ‘Do you have trouble falling 
asleep at night or do you wake up in the middle of the night?’, which did not map 
on any of our individual insomnia constructs, thus was not further analysed. 
NHIS participants reported DIS and DMS using two questions: ‘In the past week, 
how many times did you have trouble falling asleep?’ and ‘In the past week, how 
many times did you have trouble staying asleep?’, respectively. Participants who 
reported having these symptoms ‘usually’ in the UKBB and ‘≥3 times per week’ in 
the NHIS were coded as ‘yes’. These estimates were compared to the pooled IPD 
meta-analysis sample.
Statistical analyses. We explored whether the population in the meta-analysis 
was representative of the general population of the Netherlands by comparing 
the distributions of age, sex and education with the last Dutch Census in 201120. 
For descriptive purposes, we pooled the data across studies, with different studies 
contributing data for different sleep variables, according to what data had been 
collected.
First, age- and sex-specific means and prevalences of sleep variables were 
computed on the basis of systematically coded variables to reduce between-study 
heterogeneity (Supplementary Text). Due to the pooling of multiple studies, no 
statistical tests were performed at this stage. Age categories were aligned to those 
of NSF: toddlers (1–2 years), preschoolers (3–5 years), school-aged children 
(6–13 years), teenagers (14–17 years), young adults (18–25 years), adults  
(26–40 years), middle-aged adults (41–64 years) and older adults (>65 years).
Second, variations in TST, SE and TIB were plotted using age-specific 
percentiles (10th, 25th, 50th, 75th and 90th). To facilitate comparison, TST 
was also plotted against the NSF sleep duration recommendations: 11–14 h for 
toddlers, 10–13 h for preschoolers, 9–11 h for school-aged children, 8–10 h for 
teenagers, 7–9 h for adults of 26–64 years and 7–8 h for older adults3. To explore 
detailed age-related changes in TST, SE and TIB we also estimated percentile 
curves against continuous age between 1 and 100 years using gamlss R package. 
To explore heterogeneity, the I2 statistic was estimated (using two-step approach), 
which indicates the percentage of variance in a meta-analysis that is attributable to 
study heterogeneity. Also, we describe how the I2 statistic changed with subgroup 
analyses (by age group, sex and cohort). In addition, we evaluated the differences 
between the pooled estimates of sleep duration and insomnia symptom as 
estimated by a fixed-effect versus random-effects meta-analysis.
Third, we examined associations of sleep duration, sleep efficiency and 
insomnia symptoms with sociodemographic and health indicators using one-step 
approach. After testing assumptions, we used linear mixed models, with a random 
intercept for each study to account for between-study heterogeneity. The random 
effects for study were significant in all models. In these analyses, we only included 
participants aged 18 years and older as sleep characteristics change rapidly during 
childhood and adolescence9. Three models were constructed: a ‘demographic 
determinants model’ where we studied the association of mutually adjusted age 
(continuous), sex, educational level and ethnic origin with sleep variables, a ‘social 
determinants model’ where we studied the association of employment status and 
partnership on sleep variables adjusted for demographic determinants, and a 
‘health indicators model’ where we studied the association of smoking and BMI 
with sleep variables adjusted for demographic determinants.
Fourth, since sleep may change due to social changes like economic crisis 
or increasing use of blue-light emitting screens, we assessed whether changes 
in average sleep duration (TST), as well as in the prevalence of DIS and DMS, 
occurred in the Netherlands and the United States during the years of study.
As more sophisticated imputation methods cannot account for within-study 
clustering, missing values on age (0.3%) were imputed with the study-specific 
mean and a missing category was used to account for missing values in categorical 
variables (education = 0.6%, ethnic origin = 26.6%, employment = 7.4%, 
partner = 62.2%, smoking = 15.0% and BMI = 13.3%). Ethnicity was not assessed 
in eight studies, whereas of the studies in adult populations five did not assess 
employment and three did not assess smoking. Missing or implausible values on 
sleep variables were not imputed. The distribution of missing data across age and 
sex is shown in Supplementary Table 16. Data were analysed using SPSS Statistics 
v.21 (IBM Corp.) and R v.3.4.1.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
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Data availability
Our data protection agreements with the participating cohort studies do not allow 
us to share individual-level data from these studies to third parties.
Code availability
The coding protocol for data analysis is provided in the Supplementary Text. 
Scripts of the statistical analyses are available upon request.
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Mycoplasma contamination mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.
Commonly misidentified lines
(See ICLAC register)
Name any commonly misidentified cell lines used in the study and provide a rationale for their use.
Palaeontology and Archaeology
Specimen provenance Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the 
issuing authority, the date of issue, and any identifying information).
Specimen deposition Indicate where the specimens have been deposited to permit free access by other researchers.
Dating methods If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where 
they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are 
provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance 
was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.
Wild animals Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were 
caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, 
say where and when) OR state that the study did not involve wild animals.
Field-collected samples For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, 
photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Ethics oversight Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance 
was required and explain why not.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics We included 1081734 participants aged 1-100, 55% women.
Recruitment All studies used random sampling from the general population.
Ethics oversight Local Universities provided ethics approval. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol Note where the full trial protocol can be accessed OR if not available, explain why.
Data collection Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Outcomes Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.
Dual use research of concern
Policy information about dual use research of concern
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Any other significant area
Experiments of concern
Does the work involve any of these experiments of concern:
No Yes
Demonstrate how to render a vaccine ineffective
Confer resistance to therapeutically useful antibiotics or antiviral agents
Enhance the virulence of a pathogen or render a nonpathogen virulent
Increase transmissibility of a pathogen
Alter the host range of a pathogen
Enable evasion of diagnostic/detection modalities
Enable the weaponization of a biological agent or toxin
Any other potentially harmful combination of experiments and agents
ChIP-seq
Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links 
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links.  For your "Final submission" document, 
provide a link to the deposited data.
Files in database submission Provide a list of all files available in the database submission.
Genome browser session 
(e.g. UCSC)
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to 
enable peer review.  Write "no longer applicable" for "Final submission" documents.
Methodology
Replicates Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and 
whether they were paired- or single-end.
Antibodies Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot 
number.
Peak calling parameters Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files 
used.
Data quality Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community 
repository, provide accession details.
5







The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Instrument Identify the instrument used for data collection, specifying make and model number.
Software Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a 
community repository, provide accession details.
Cell population abundance Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the 
samples and how it was determined.
Gating strategy Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell 
population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonance imaging
Experimental design
Design type Indicate task or resting state; event-related or block design.
Design specifications Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial 
or block (if trials are blocked) and interval between trials.
Behavioral performance measures State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used 
to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across 
subjects).
Acquisition
Imaging type(s) Specify: functional, structural, diffusion, perfusion.
Field strength Specify in Tesla
Sequence & imaging parameters Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, 
slice thickness, orientation and TE/TR/flip angle.
Area of acquisition State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
Diffusion MRI Used Not used
Preprocessing
Preprocessing software Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, 
segmentation, smoothing kernel size, etc.).
Normalization If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for 
transformation OR indicate that data were not normalized and explain rationale for lack of normalization.
Normalization template Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. 
original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.
Noise and artifact removal Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and 
physiological signals (heart rate, respiration).
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Volume censoring Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.
Statistical modeling & inference
Model type and settings Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and 
second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).
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Statistic type for inference
(See Eklund et al. 2016)
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Correction Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).
Models & analysis
n/a Involved in the study
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Graph analysis
Multivariate modeling or predictive analysis
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subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, 
etc.).
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